2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Carbonic Anhydrase
  5. CA XIV Isoform

CA XIV

Carbonic anhydrase XIV (CA XIV) is a membrane-bound carbonic anhydrase first isolated from mouse kidney, and human CA14 was cloned and mapped as a distinct gene[1][2]. It supports CO₂/HCO₃⁻ conversion, linking extracellular acid-base regulation with bicarbonate handling in kidney, brain, retina, and skeletal muscle models[3][4][5][6][7][8][9]. Mechanistically, CA XIV contributes to extracellular buffering in brain and interacts with the AE3 Cl⁻/HCO₃⁻ exchanger, connecting enzyme activity to bicarbonate homeostasis in excitable tissues[5][8]. In disease-relevant models, CA XIV deficiency caused a functional defect in the retinal light response, while retinal studies localized CA XIV to retinal pigment epithelium, Müller cells, and astrocytes[6][7]. Compared with related isoforms, CA XIV differs from CA IV in brain buffering roles and from CA XIII/XV by being a membrane-associated isoform with distinct characterization and inhibition profiles[5][10]. For experimental applications, sulfonamides, natural polyphenols, and phenolic acids provide inhibitor classes for comparing CA XIV with mammalian isoforms I-XIV[10][11].

References:

CA XIV Related Products (2):

Cat. No. Product Name Effect Purity
  • HY-109056
    Elsulfavirine
    		Inhibitor 99.90%
    Elsulfavirine (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine is used in studies related to HIV-1 infection and liver cancer.
  • HY-109056A
    Elsulfavirine sodium
    		Inhibitor
    Elsulfavirine sodium (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine sodium also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine sodium and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine sodium is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine sodium exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine sodium is used in studies related to HIV-1 infection and liver cancer.